# OnCo record nct06178159 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06178159/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06178159", "NCT06178159" ;
  schema:name "DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer"@en ;
  schema:description "A phase 2 trial of Disitamab vedotin, Pertuzumab and Toripalimab in HER2-positive breast cancer, run by RemeGen Co., Ltd., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06178159/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06178159> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2023-11-28" ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/her2-positive-early-breast-cancer/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:drugs <https://onco.cc/drugs/disitamab-vedotin/>, <https://onco.cc/drugs/pertuzumab/>, <https://onco.cc/drugs/toripalimab/> ;
  onco:companies <https://onco.cc/companies/remegen/> .